| Name | Title | Contact Details |
|---|
Architectural Concepts is a Denver, CO-based company in the Business Services sector.
At Aktiv, we amplify functional training spaces for health clubs, boutique studios, and fitness amenities alike. Our mission is to design safe, and supremely functional spaces supporting our clients delivery of inspirational exercise experiences. OUR EXPERIENCE Aktiv is the leading expert in functional fitness facility supply and design. We balance exercise trend and technology to create exceptional user engagement, both indoors and outside. Aktivs end-to-end solutions equip commercial and residential fitness spaces with premium products and digital guidance powering todays most sought-after workouts. OUR DESIGN Our creative process establishes intention, efficiency, and user experience for every project. We incorporate leading architectural and interior design principles with the latest in exercise trend and equipment solution. OUR SOLUTIONS GYM RAX® is the worlds leading fitness rigging solution for modular storage and equipment suspension. Aktiv harnesses the power of movement-based modalities in every product we design. Together with our integration partners, Aktiv delivers complete end-to-end solutions designed to wow members, guests, and residents alike. For more information, visit aktivsolutions.com A Fitness Ventures International, LLC Company All Rights Reserved.
Dallas Decal Inc is a Rowlett, TX-based company in the Business Services sector.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.
Almond and Assoc is a Tacoma, WA-based company in the Business Services sector.